Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.25 USD 3.21% Market Closed
Market Cap: 598.8m USD
Have any thoughts about
Autolus Therapeutics PLC?
Write Note

Autolus Therapeutics PLC
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Autolus Therapeutics PLC
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash Taxes Paid
$551k
CAGR 3-Years
-33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash Taxes Paid
$2.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Cash Taxes Paid
-ÂŁ29.2m
CAGR 3-Years
-92%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash Taxes Paid
$694k
CAGR 3-Years
98%
CAGR 5-Years
58%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash Taxes Paid
ÂŁ977k
CAGR 3-Years
N/A
CAGR 5-Years
69%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash Taxes Paid
ÂŁ21.5m
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
8%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
598.8m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
5.07 USD
Undervaluation 56%
Intrinsic Value
Price

See Also

What is Autolus Therapeutics PLC's Cash Taxes Paid?
Cash Taxes Paid
551k USD

Based on the financial report for Dec 31, 2023, Autolus Therapeutics PLC's Cash Taxes Paid amounts to 551k USD.

What is Autolus Therapeutics PLC's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 3Y
-33%

Over the last year, the Cash Taxes Paid growth was 17%. The average annual Cash Taxes Paid growth rates for Autolus Therapeutics PLC have been -33% over the past three years .

Back to Top